Immunosuppression May not Change Renal Outcomes in IgA Nephropathy
In patients with IgA nephropathy (IgAN), no differences in renal outcomes were observed between immunosuppression plus supportive care versus supportive care alone over 10 years follow-up, according to study results published in Kidney International.
Follow-up data from 149 participants of the STOP-IgAN trial in patients with IgAN and substantial proteinuria were analyzed.
The primary endpoint of time to first occurrence of a composite of death, end-stage kidney disease (ESKD), or a decline of over 40% in the estimated glomerular filtration rate (eGFR) compared to baseline at randomization into STOP-IgAN, was met in 35 of 77 patients in the immunosuppression group and 36 of 72 patients in the supportive care group. In patients with supportive care. Seventeen patients in the supportive care group and 20 in the immunosuppression group developed ESKD.
Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020; doi:10.1016/j.kint.2020.04.046.